Phase II study of paclitaxel in patients with soft tissue sarcomas

Sarcoma

Volumn 1, Issue 2, 1997, Pages 95-97

  Patel, Shreyaskumar R ^a,b   Linke, Kaye A ^a   Burgess, M Andrew ^a   Papadopoulos, Nicholas E ^a   Plager, Carl ^a   Jenkins, Jan ^a   Benjamin, Robert ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Paclitaxel (Taxol); Soft tissue sarcomas

Indexed keywords

EID: 0002486053     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577149778362     Document Type: Article

References (5)

1. Rowinsky EK, Donehower RC. Drug therapy: paclitaxel (Taxol). N Engl J Med 1995; 332:1004-14.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
3. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin 1996; 46:8.
4. Patel SR, Papadopoulos N, Plager C, et al. Phase II study of Paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 1996; 78:741-4.
5. Balcerzak SP, Benedetti J, Weiss GR, et al. A phase II trial of Paclitaxel in patients with advanced soft-tissue sarcomas - a Southwest Oncology Group Study. Cancer 1995; 76:2248-52.